| 1 |
Mak LY, Hui RW, Cheung KS, Fung J, Seto WK, Yuen MF. Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers. Expert Opin Drug Discov 2023;:1-16. [PMID: 36943183 DOI: 10.1080/17460441.2023.2192920] [Reference Citation Analysis]
|
| 2 |
Tang Q, Ye J, Zhang Y, Zhang P, Xia G, Zhu J, Wei S, Li X, Zhang Z. Establishment of a multi-parameter prediction model for the functional cure of HBeAg-negative chronic hepatitis B patients treated with pegylated interferonα and decision process based on response-guided therapy strategy.. [DOI: 10.21203/rs.3.rs-2609916/v1] [Reference Citation Analysis]
|
| 3 |
Xie Y, Li M, Ou X, Zheng S, Gao Y, Xu X, Yang Y, Ma A, Li J, Nan Y, Zheng H, Liu J, Wei L, Feng B. HBsAg ≤ 135 IU/mL or HBcrAg ≤ 3.6 logU/mL was associated with HBsAg loss after nucleos(t)ide analogue cessation.. [DOI: 10.21203/rs.3.rs-2611117/v1] [Reference Citation Analysis]
|
| 4 |
Nguyen T, Melnikova L, Ilchenko L, Kyuregyan K, Gordeychuk I, Bondarenko N. Clinical and virological characteristics of chronic hepatitis b and response to antiviral therapy. MES 2023. [DOI: 10.47183/mes.2023.003] [Reference Citation Analysis]
|
| 5 |
Lim SG, Baumert TF, Boni C, Gane E, Levrero M, Lok AS, Maini MK, Terrault NA, Zoulim F. The scientific basis of combination therapy for chronic hepatitis B functional cure. Nat Rev Gastroenterol Hepatol 2023. [PMID: 36631717 DOI: 10.1038/s41575-022-00724-5] [Reference Citation Analysis]
|
| 6 |
Suzuki T, Matsuura K, Urakabe K, Okumura F, Kawamura H, Sobue S, Matoya S, Miyaki T, Kimura Y, Kato D, Kusakabe A, Tanaka Y, Ozasa A, Nagura Y, Fujiwara K, Nojiri S, Hagiwara S, Kusumoto S, Inoue T, Tanaka Y, Kataoka H. Outcome of nucleos(t)ide analog cessation in patients with treatment for prevention of or against hepatitis B virus reactivation. Hepatol Res 2022. [PMID: 36461885 DOI: 10.1111/hepr.13864] [Reference Citation Analysis]
|
| 7 |
Mitchell T, Nayagam JS, Dusheiko G, Agarwal K. Health inequalities in the management of chronic hepatitis B virus infection in patients from sub-Saharan Africa in high-income countries. JHEP Rep 2023;5:100623. [PMID: 36636709 DOI: 10.1016/j.jhepr.2022.100623] [Reference Citation Analysis]
|
| 8 |
Hu Q, Qi X, Yu Y, Gao Y, Zhang X, Wang Q, Zhang X, Zhuo Y, Li J, Zhang J, Chen L, Huang Y. The efficacy and safety of adding on or switching to peginterferon α-2b in HBeAg-positive chronic hepatitis B patients with long-term entecavir treatment: a multicentre randomised controlled trial. Aliment Pharmacol Ther 2022;56:1394-407. [PMID: 36128636 DOI: 10.1111/apt.17222] [Reference Citation Analysis]
|
| 9 |
Peng CW, Jeng WJ, Yang HI, Liu YC, Chien RN, Liaw YF. A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off-therapy relapse: An observational study. J Gastroenterol Hepatol 2022;37:2164-72. [PMID: 35869752 DOI: 10.1111/jgh.15966] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Papatheodoridi M, Papachristou E, Moschidis Z, Hadziyannis E, Rigopoulou E, Zachou K, Villeret F, Magiorkinis G, Lyberopoulou A, Gatselis N, Vlachogiannakos I, Manolakopoulos S, Dalekos GN, Zoulim F, Paraskevis D, Papatheodoridis GV. Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy. J Viral Hepat 2022;29:948-57. [PMID: 35789515 DOI: 10.1111/jvh.13729] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Tseng C, Chen T, Wu J, Lee T, Borghi JA, Lin J, Nguyen MH, Hsu Y. Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100617] [Reference Citation Analysis]
|
| 12 |
Leroy V, Chevaliez S, Decraecker M, Roulot D, Nana J, Asselah T, Causse X, Durantel D, Thibaut V, Ganne-Carrié N, Bureau C, de Lédinghen V, Bourlière M. Non-invasive diagnosis and follow-up of chronic infection with hepatitis B virus. Clin Res Hepatol Gastroenterol 2022;46:101773. [PMID: 34332134 DOI: 10.1016/j.clinre.2021.101773] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 13 |
Yang X, Zhang K, Xu Q, Shu X, Mo Z, Xie D, Gao Z, Deng H. Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg. Front Immunol 2022;13:997608. [DOI: 10.3389/fimmu.2022.997608] [Reference Citation Analysis]
|
| 14 |
Fung S, Choi HSJ, Gehring A, Janssen HLA. Getting to HBV cure: The promising paths forward. Hepatology 2022;76:233-50. [PMID: 34990029 DOI: 10.1002/hep.32314] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 15 |
Broquetas T, Carrión JA. Current Perspectives on Nucleos(t)ide Analogue Therapy for the Long-Term Treatment of Hepatitis B Virus. HMER 2022;Volume 14:87-100. [DOI: 10.2147/hmer.s291976] [Reference Citation Analysis]
|
| 16 |
Azhari H, Frolkis AD, Shaheen AA, Israelson H, Pinto J, Congly SE, Borman MA, Aspinall AA, Stinton LM, Nguyen HH, Swain MG, Burak KW, Lee SS, Sadler MD, Coffin CS. Real-world tertiary referral centre experience stopping nucleos(t)ide analogue therapy in patients with chronic hepatitis B. CanLivJ 2022. [DOI: 10.3138/canlivj-2022-0002] [Reference Citation Analysis]
|
| 17 |
Liao G, Liu Z, Xia M, Chen H, Wu H, Li B, Yu T, Cai S, Zhang X, Peng J. Soluble Programmed Cell Death-1 is a Novel Predictor of HBsAg Loss in Chronic Hepatitis B Patients When Long-Term Nucleos(t)ide Analog Treatment is Discontinued. IDR 2022;Volume 15:2347-57. [DOI: 10.2147/idr.s360202] [Reference Citation Analysis]
|
| 18 |
Luo M, Zhou B, Hou J, Jiang D. Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients. Hepatol Res 2022;52:337-51. [PMID: 35089634 DOI: 10.1111/hepr.13749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 19 |
Colombatto P, Coco B, Bonino F, Brunetto MR. Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine. Viruses 2022;14:701. [DOI: 10.3390/v14040701] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 20 |
Moini M, Fung S. HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure. Viruses 2022;14. [PMID: 35458387 DOI: 10.3390/v14040657] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 21 |
Hirode G, Choi HSJ, Chen CH, Su TH, Seto WK, Van Hees S, Papatheodoridi M, Lens S, Wong G, Brakenhoff SM, Chien RN, Feld J, Sonneveld MJ, Chan HLY, Forns X, Papatheodoridis GV, Vanwolleghem T, Yuen MF, Hsu YC, Kao JH, Cornberg M, Hansen BE, Jeng WJ, Janssen HLA; RETRACT-B Study Group. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). Gastroenterology 2022;162:757-771.e4. [PMID: 34762906 DOI: 10.1053/j.gastro.2021.11.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 27.0] [Reference Citation Analysis]
|
| 22 |
Papatheodoridi M, Su TH, Hadziyannis E, Liao CH, Orfanidou Α, Yang HC, Zachou K, Liu CJ, Kourikou A, Gatselis N, Manolakopoulos S, Dalekos G, Kao JH, Hadziyannis S, Papatheodoridis GV. Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study. Liver Int 2022;42:541-50. [PMID: 34890120 DOI: 10.1111/liv.15128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 23 |
Kaewdech A, Assawasuwannakit S, Sripongpun P, Chamroonkul N, Tangkijvanich P, Piratvisuth T. Clinical Utility of SCALE-B to Predict Hepatitis B Virus Relapse, Hepatitis B Surface Antigen Loss After Antiviral Cessation in Asian Patients After 2-Year Follow-up. Front Med (Lausanne) 2022;9:859430. [PMID: 35402452 DOI: 10.3389/fmed.2022.859430] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 24 |
Furquim d'Almeida A, Ho E, Van Hees S, Vanwolleghem T. Clinical management of chronic hepatitis B: A concise overview. United European Gastroenterol J 2021. [PMID: 34846093 DOI: 10.1002/ueg2.12176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 25 |
Huang DQ, Kew GS, Lim SG. Controversies in Treating Chronic Hepatitis B virus: The Role of Hepatitis B Virus DNA and Surface Antigen Titer. Clin Liver Dis 2021;25:763-84. [PMID: 34593152 DOI: 10.1016/j.cld.2021.06.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 26 |
Lim JH, Yu JH, Suh YJ, Lee JW, Jin YJ. Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir. Medicine (Baltimore) 2021;100:e27417. [PMID: 34596169 DOI: 10.1097/MD.0000000000027417] [Reference Citation Analysis]
|
| 27 |
Meena BL, Premkumar M, Roy A, Singh V. Is HBV RNA a valid marker for predicting sustained viral response for nucleoside analogue cessation? Gut 2021;70:2008-9. [PMID: 33158981 DOI: 10.1136/gutjnl-2020-323360] [Reference Citation Analysis]
|
| 28 |
Xu WX, Li YM, Li JG, Mei YY, Chen YM, Li XJ, Lin CS, Deng H, Zhao ZX, Xie DY, Gao ZL, Peng L. The 96-week clinical outcomes after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients. Gastroenterol Rep (Oxf) 2021;9:313-22. [PMID: 34567563 DOI: 10.1093/gastro/goab013] [Reference Citation Analysis]
|
| 29 |
Kaewdech A, Sripongpun P. Challenges in the discontinuation of chronic hepatitis B antiviral agents. World J Hepatol 2021;13:1042-57. [PMID: 34630873 DOI: 10.4254/wjh.v13.i9.1042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 30 |
Jaroenlapnopparat A, Chayanupatkul M, Tangkijvanich P. Novel viral markers and the prediction of off-treatment relapse in chronic hepatitis B patients: A systematic review. J Gastroenterol Hepatol 2021;36:2349-62. [PMID: 33811375 DOI: 10.1111/jgh.15516] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 31 |
Chen H, Ding X, Liao G, Xia M, Ren Z, Fan R, Peng J. Hepatitis B surface antigen kinetics after discontinuation of and retreatment with oral antivirals in non-cirrhotic HBeAg-positive chronic hepatitis B. J Viral Hepat 2021;28:1121-9. [PMID: 33899998 DOI: 10.1111/jvh.13526] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 32 |
Berg T, Lampertico P. The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy. J Hepatol 2021;75:474-80. [PMID: 33957187 DOI: 10.1016/j.jhep.2021.04.040] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 15.0] [Reference Citation Analysis]
|
| 33 |
Huang PY, Wang JH, Hung CH, Lu SN, Hu TH, Chen CH. The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients. J Viral Hepat 2021;28:1141-9. [PMID: 33932245 DOI: 10.1111/jvh.13528] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 34 |
Caviglia GP, Troshina Y, Garro E, Gesualdo M, Aneli S, Birolo G, Pittaluga F, Cavallo R, Saracco GM, Ciancio A. Usefulness of a Hepatitis B Surface Antigen-Based Model for the Prediction of Functional Cure in Patients with Chronic Hepatitis B Virus Infection Treated with Nucleos(t)ide Analogues: A Real-World Study. J Clin Med 2021;10:3308. [PMID: 34362093 DOI: 10.3390/jcm10153308] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 35 |
Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, Yuen MF. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int 2021;15:833-51. [PMID: 34297329 DOI: 10.1007/s12072-021-10223-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 36 |
Cheng Y, Ji Y, Duan H, Li Y, Lau G, Wang F. What Should Be Done to Re-evaluate Cessation of Nucleos(t)ide Analog Therapy for Chronic Hepatitis B Infection? Infectious Diseases & Immunity 2021;1:93-102. [DOI: 10.1097/id9.0000000000000014] [Reference Citation Analysis]
|
| 37 |
Maravelia P, Frelin L, Ni Y, Caro Pérez N, Ahlén G, Jagya N, Verch G, Verhoye L, Pater L, Johansson M, Pasetto A, Meuleman P, Urban S, Sällberg M. Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections. J Infect Dis 2021;223:128-38. [PMID: 31994701 DOI: 10.1093/infdis/jiaa036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 38 |
Li T, Liang Y, Zhang M, Liu F, Zhang L, Yang B, Wang L. Nucleoside/nucleotide analog consolidation therapy in hepatitis B e-antigen positive chronic hepatitis B patients: Three years should be preferred. Hepatol Res 2021;51:633-40. [PMID: 33772988 DOI: 10.1111/hepr.13641] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 39 |
Xue Y, Zhang M, Li T, Liu F, Zhang LX, Fan XP, Yang BH, Wang L. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World J Gastroenterol 2021; 27(14): 1497-1506 [PMID: 33911470 DOI: 10.3748/wjg.v27.i14.1497] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 40 |
Seto WK, Liu KS, Mak LY, Cloherty G, Wong DK, Gersch J, Lam YF, Cheung KS, Chow N, Ko KL, To WP, Fung J, Yuen MF. Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation. Gut 2021;70:775-83. [PMID: 32759300 DOI: 10.1136/gutjnl-2020-321116] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 13.5] [Reference Citation Analysis]
|
| 41 |
Kuo YH, Wang JH, Hung CH, Lu SN, Hu TH, Chen CH. Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation. Hepatol Int 2021;15:301-9. [PMID: 33665773 DOI: 10.1007/s12072-021-10159-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 42 |
Chan HL. Letter to the Editor: Use of Pregenomic Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen to Predict Cure of Hepatitis B Virus Infection. Hepatology 2021;73:870. [PMID: 32687649 DOI: 10.1002/hep.31469] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 43 |
Bong JH, Kim HR, Jung J, Park JH, Sung JS, Lee CK, Choi KH, Shin SS, Kang MJ, Kim HO, Lee DY, Pyun JC. Switching-peptides for one-step immunoassay and its application to the diagnosis of human hepatitis B. Biosens Bioelectron 2021;178:112996. [PMID: 33524706 DOI: 10.1016/j.bios.2021.112996] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 44 |
Huang DQ, Lim SG. Life After s Loss: Impact of Hepatitis B s Antigen Loss on Future Patient Outcomes. Clin Liver Dis (Hoboken) 2020;16:262-5. [PMID: 33489099 DOI: 10.1002/cld.983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 45 |
Manolakopoulos S, Kranidioti H, Kourikou A, Deutsch MM, Triantos C, Tsolias C, Manesis EK, Mathou N, Alexopoulou A, Hadziyannis E, Papatheodoridis G. Long-term clinical outcome of HBeAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues. Liver Int 2021;41:48-57. [PMID: 33373114 DOI: 10.1111/liv.14654] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 46 |
Xie Y, Li M, Ou X, Zheng S, Gao Y, Xu X, Yang Y, Ma A, Li J, Huang Y, Nan Y, Zheng H, Feng B. HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation. J Gastroenterol 2021;56:856-67. [PMID: 34292372 DOI: 10.1007/s00535-021-01812-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 47 |
Tout I, Lampertico P, Berg T, Asselah T. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antiviral Res 2021;185:104992. [PMID: 33279523 DOI: 10.1016/j.antiviral.2020.104992] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 48 |
Chiu SM, Kuo YH, Wang JH, Hung CH, Hu TH, Lu SN, Chen CH. Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy. Clin Gastroenterol Hepatol 2020;18:2989-2997.e3. [PMID: 32353534 DOI: 10.1016/j.cgh.2020.04.048] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 49 |
Kaewdech A, Tangkijvanich P, Sripongpun P, Witeerungrot T, Jandee S, Tanaka Y, Piratvisuth T. Hepatitis B surface antigen, core-related antigen and HBV RNA: Predicting clinical relapse after NA therapy discontinuation. Liver Int 2020;40:2961-71. [PMID: 32668074 DOI: 10.1111/liv.14606] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 50 |
Rodríguez M, Buti M, Esteban R, Lens S, Prieto M, Suárez E, García-samaniego J. Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). Gastroenterología y Hepatología (English Edition) 2020;43:559-587. [DOI: 10.1016/j.gastre.2020.03.008] [Reference Citation Analysis]
|
| 51 |
Tseng TN, Hu TH, Wang JH, Kuo YH, Hung CH, Lu SN, Jeng WJ, Chen CH. Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL. Clin Gastroenterol Hepatol 2020;18:2803-2812.e2. [PMID: 32360818 DOI: 10.1016/j.cgh.2020.04.037] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 52 |
Tamori A, Kimura K, Kioka K, Enomoto H, Odagiri N, Kozuka R, Uchida-Kobayashi S, Enomoto M, Kawada N, Mizokami M. Outcome of nucleos(t)ide analog intervention in patients with preventive or on-demand therapy for hepatitis B virus reactivation. J Med Virol 2021;93:3679-87. [PMID: 32940921 DOI: 10.1002/jmv.26526] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 53 |
Liu Y, Xue J, Liao W, Yan H, Liang X. Serum HBV RNA Dynamic and Drug Withdrawal Predictor Value in Patients With Chronic HBV Infection on Long-term Nucleos(t)ide Analogue (NA) Therapy. J Clin Gastroenterol 2020;54:e73-82. [PMID: 32604147 DOI: 10.1097/MCG.0000000000001376] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 54 |
Hall S, Howell J, Visvanathan K, Thompson A. The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy. Viruses 2020;12:E934. [PMID: 32854335 DOI: 10.3390/v12090934] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 55 |
Rodríguez M, Buti M, Esteban R, Lens S, Prieto M, Suárez E, García-Samaniego J. Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). Gastroenterol Hepatol 2020;43:559-87. [PMID: 32778356 DOI: 10.1016/j.gastrohep.2020.03.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 56 |
Li X, Zhang L, Qiu M, Huang Y, Xiao H, Lu B, Jiang Y, Long F, Lin H, He J, Wu Q, Zhang M, Wang L, Zhu X, Gong M, Sun X, Sun J, Sun F, Lu W, Xu W, Chen G, Li Z, Gan D, Yang X, Du H, Ye Y. Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multicener, double-blind, randomized controlled trial in China. Trials 2020;21:708. [PMID: 32787905 DOI: 10.1186/s13063-020-04417-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 57 |
Tout I, Loureiro D, Mansouri A, Soumelis V, Boyer N, Asselah T. Hepatitis B surface antigen seroclearance: Immune mechanisms, clinical impact, importance for drug development. J Hepatol 2020;73:409-22. [PMID: 32333923 DOI: 10.1016/j.jhep.2020.04.013] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 58 |
Jiang S, Zhang Y, Li Q, Qiu L, Bian B. KIAA1522 Promotes the Progression of Hepatocellular Carcinoma via the Activation of the Wnt/β-Catenin Signaling Pathway. Onco Targets Ther 2020;13:5657-68. [PMID: 32606779 DOI: 10.2147/OTT.S251157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 59 |
Carey I, Gersch J, Wang B, Moigboi C, Kuhns M, Cloherty G, Dusheiko G, Agarwal K. Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy. Hepatology 2020;72:42-57. [PMID: 31701544 DOI: 10.1002/hep.31026] [Cited by in Crossref: 77] [Cited by in F6Publishing: 77] [Article Influence: 25.7] [Reference Citation Analysis]
|
| 60 |
Pronier C, Candotti D, Boizeau L, Bomo J, Laperche S, Thibault V. The contribution of more sensitive hepatitis B surface antigen assays to detecting and monitoring hepatitis B infection. J Clin Virol 2020;129:104507. [PMID: 32570044 DOI: 10.1016/j.jcv.2020.104507] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 61 |
Yang R, Cui L, Liu Y, Cong X, Fei R, Wu S, Wei L. A hook-effect-free homogeneous light-initiated chemiluminescence assay: is it reliable for screening and the quantification of the hepatitis B surface antigen? Ann Transl Med 2020;8:606. [PMID: 32566632 DOI: 10.21037/atm.2020.02.59] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 62 |
Hadziyannis E, Hadziyannis S. Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B. Expert Rev Gastroenterol Hepatol 2020;14:243-51. [PMID: 32162562 DOI: 10.1080/17474124.2020.1738219] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 63 |
Liem KS, Gehring AJ, Feld JJ, Janssen HLA. Challenges With Stopping Long-term Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B. Gastroenterology 2020;158:1185-90. [PMID: 31809724 DOI: 10.1053/j.gastro.2019.10.050] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 64 |
Papatheodoridi M, Papatheodoridis G. Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B. Cells. 2020;9. [PMID: 32093411 DOI: 10.3390/cells9020493] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 65 |
Liem KS, Fung S, Wong DK, Yim C, Noureldin S, Chen J, Feld JJ, Hansen BE, Janssen HLA. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). Gut 2019;68:2206-13. [PMID: 31462554 DOI: 10.1136/gutjnl-2019-318981] [Cited by in Crossref: 84] [Cited by in F6Publishing: 86] [Article Influence: 21.0] [Reference Citation Analysis]
|
| 66 |
Kao JH, Berg T. Nucleos(t)ide analogues in patients with chronic hepatitis B: to stop or not to stop? Gut 2019;68:2105-6. [PMID: 31527067 DOI: 10.1136/gutjnl-2019-319648] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 67 |
Mak LY, Seto WK, Fung J, Yuen MF. Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B. Hepatol Int 2020;14:35-46. [PMID: 31745711 DOI: 10.1007/s12072-019-09998-5] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 68 |
Chen C, Hu T, Wang J, Lai H, Hung C, Lu S, Peng C. Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy. Hepatol Int 2020;14:317-25. [DOI: 10.1007/s12072-019-09991-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 69 |
Liu J, Li T, Zhang L, Xu A. Reply. Hepatology 2019;70:1489-90. [PMID: 30779450 DOI: 10.1002/hep.30573] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 70 |
Ho E, Van Hees S, Goethals S, Smits E, Huizing M, Francque S, De Winter B, Michielsen P, Vanwolleghem T. Biobanking for Viral Hepatitis Research. Front Med (Lausanne) 2019;6:183. [PMID: 31482092 DOI: 10.3389/fmed.2019.00183] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 71 |
Hong T, Yang H, Kao J. Role of HBsAg Testing in the Management of Patients with Chronic HBV. Curr Hepatology Rep 2019;18:331-41. [DOI: 10.1007/s11901-019-00484-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 72 |
Wu YL, Shen CL, Chen XY. Antiviral treatment for chronic hepatitis B: Safety, effectiveness, and prognosis. World J Clin Cases 2019; 7(14): 1784-1794 [PMID: 31417924 DOI: 10.12998/wjcc.v7.i14.1784] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 73 |
Xu WX, Peng L. Response to: Comment on "48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse". Can J Gastroenterol Hepatol 2019;2019:2970510. [PMID: 31187027 DOI: 10.1155/2019/2970510] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 74 |
Li T, Liu J, Zhang L, Xu A. Reply. Hepatology 2019;69:1844. [PMID: 30703254 DOI: 10.1002/hep.30531] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 75 |
Wang CC, Kao JH. The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogue Cessation Among Asian Chronic Hepatitis B Patients: Friend or Foe? Hepatology 2019;69:1843. [PMID: 30703245 DOI: 10.1002/hep.30532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
